Key Points
- Director Patrick Enright purchased 5,882 shares on Dec. 11 at $42.50 each for a total of $249,985, a transaction disclosed in an SEC filing.
- Vera is a clinical‑stage biotech whose lead candidate, atacicept, is in Phase III for IgA nephropathy; the company recently reported quarterly EPS of -$1.26 (missing estimates) and holds an average analyst rating of "Moderate Buy" with a $66.58 average price target.
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) Director Patrick Enright acquired 5,882 shares of the firm's stock in a transaction that occurred on Thursday, December 11th. The stock was purchased at an average price of $42.50 per share, with a total value of $249,985.00. Following the completion of the acquisition, the director directly owned 5,882 shares of the company's stock, valued at $249,985. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Vera Therapeutics Stock Down 1.2%
Shares of Vera Therapeutics stock opened at $49.21 on Tuesday. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.19. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of -12.33 and a beta of 1.21. The firm's 50-day moving average is $32.42 and its two-hundred day moving average is $26.67.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the previous year, the firm earned ($0.85) EPS. As a group, research analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Vera Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. increased its holdings in Vera Therapeutics by 24.3% in the 1st quarter. Invesco Ltd. now owns 27,297 shares of the company's stock worth $656,000 after buying an additional 5,343 shares during the period. Nuveen LLC acquired a new stake in Vera Therapeutics during the 1st quarter valued at approximately $3,768,000. Russell Investments Group Ltd. boosted its holdings in shares of Vera Therapeutics by 505.1% in the 1st quarter. Russell Investments Group Ltd. now owns 152,918 shares of the company's stock valued at $3,673,000 after acquiring an additional 127,646 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Vera Therapeutics in the first quarter worth $471,000. Finally, Algert Global LLC raised its holdings in shares of Vera Therapeutics by 81.6% during the first quarter. Algert Global LLC now owns 70,010 shares of the company's stock worth $1,682,000 after purchasing an additional 31,460 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have recently commented on VERA. HC Wainwright reissued a "buy" rating and issued a $90.00 price target on shares of Vera Therapeutics in a research report on Friday, November 28th. Wedbush boosted their target price on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a "neutral" rating in a report on Thursday. Weiss Ratings restated a "sell (d-)" rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. Bank of America began coverage on shares of Vera Therapeutics in a research report on Thursday, October 16th. They issued a "buy" rating and a $48.00 price objective on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Vera Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $66.58.
View Our Latest Report on VERA
Vera Therapeutics Company Profile
(
Get Free Report)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
